% | $
Quotes you view appear here for quick access.

VistaGen Therapeutics, Inc. Message Board

  • hwmccusker hwmccusker Jan 23, 2013 9:29 AM Flag

    A P1 Safety Study of AV-101 for Chronic Neuropathic Pain

    The Bottom Line: The primary safety and tolerability endpoints of the P1 program were met. Let’s see how the P2 study progresses for the treatment of pain. VSTA closed at $0.79 on 1/22/13 with increasing volume of 13.5 K shares from the past days of 0. Look for VSTA to open up for the day!

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I just added $VSTA at $.60 after someone convinced me of the massive upside we could see here on any one of a few approvals. I do not know the Other medical companies pursuing these novel candidate solutions, but we have a HUGE upside at this price if we only partially succeed.

      Sentiment: Strong Buy

5.500.00(0.00%)May 10 3:49 PMEDT